Topical tacrolimus for the treatment of secondary lymphedema
Secondary lymphedema is a debilitating disease with no cure. Here the authors show that topical application of an FDA-approved anti-T cell drug tacrolimus potently prevents development and alleviates pathologic changes of established lymphedema in mice, suggesting a new treatment for human patients.
Guardado en:
Autores principales: | Jason C. Gardenier, Raghu P. Kataru, Geoffrey E. Hespe, Ira L. Savetsky, Jeremy S. Torrisi, Gabriela D. García Nores, Dawit K. Jowhar, Matthew D. Nitti, Ryan C. Schofield, Dean C. Carlow, Babak J. Mehrara |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8ae0ff4c3d0e4e30a638ec12178b9f93 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema
por: Gabriela D. García Nores, et al.
Publicado: (2018) -
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
por: Dániel Szőke, et al.
Publicado: (2021) -
Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
por: Shoughy SS, et al.
Publicado: (2016) -
Advances in surgical treatment of lymphedema
por: Maureen Beederman, et al.
Publicado: (2021) -
Lymphaticovenous Anastomosis for Age-Related Lymphedema
por: Shuhei Yoshida, et al.
Publicado: (2021)